Variables | MG (n = 15) | NMG (n = 37) | P-value |
---|---|---|---|
Age (years) | 68 (38–83) | 67 (46–86) | 0.864†|
Sex |  |  | 0.525¶ |
 Male | 9 (60.0) | 26 (70.3) |  |
 Female | 6 (40.0) | 11 (29.7) |  |
BMI (kg/m2) | 23.4 (20.8–28.3) | 24.4 (15.1–31.5) | 0.473†|
ASA score |  |  | 0.254¶ |
 1 | 0 | 4 (10.8) |  |
 2 | 15 (100) | 30 (81.1) |  |
 Unknown | 0 | 3 (8.1) |  |
Past history | Â | Â | Â |
 Diabetes | 5 (33.3) | 8 (21.6) | 0.483¶ |
 Cardiovascular disease | 7 (46.7) | 18 (48.6) | 0.897¶ |
 Others | 5 (33.3) | 13 (35.1) | 0.902¶ |
Baseline tumor markers | Â | Â | Â |
 CEA (ng/mL) | 2.9 (0.5–43.7) | 2.9 (0.6–44.9) | 0.992†|
 CA 19-9 (U/mL) | 4.2 (1.2–184.7) | 12.1 (1.2–1222.8) | 0.010†,** |
Tumor distance from the AV (cm) | 3.6 (0–10.0) | 6.0 (2.0–10.0) | 0.008†,** |
MRF involvement |  |  | 0.314¶ |
 Yes | 10 (66.7) | 19 (51.4) |  |
 No | 5 (33.3) | 18 (48.6) |  |
cT before NCRT |  |  | 0.412¶ |
 cT2 | 1 (6.7) | 0 |  |
 cT3 | 12 (80.0) | 32 (86.5) |  |
 cT4 | 2 (13.3) | 5 (13.5) |  |
cN before NCRT |  |  | 0.086¶ |
 cN0 | 0 | 3 (8.1) |  |
 cN1 | 7 (46.7) | 6 (16.2) |  |
 cN2 | 8 (53.3) | 28 (75.7) |  |
Baseline clinical stage (AJCC 8th edition) |  |  | 0.548¶ |
 Stage II | 0 | 3 (8.1) |  |
 Stage III | 15 (100) | 34 (91.9) |  |